NO852427L - PROCEDURE FOR THE MANUFACTURE OF MEDICAL, COSMETIC PREPARATIONS - Google Patents
PROCEDURE FOR THE MANUFACTURE OF MEDICAL, COSMETIC PREPARATIONSInfo
- Publication number
- NO852427L NO852427L NO852427A NO852427A NO852427L NO 852427 L NO852427 L NO 852427L NO 852427 A NO852427 A NO 852427A NO 852427 A NO852427 A NO 852427A NO 852427 L NO852427 L NO 852427L
- Authority
- NO
- Norway
- Prior art keywords
- procedure
- substances
- reacted
- protein
- blood
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 17
- 238000002360 preparation method Methods 0.000 title claims description 16
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 239000002537 cosmetic Substances 0.000 title claims description 4
- 239000011573 trace mineral Substances 0.000 claims description 19
- 235000013619 trace mineral Nutrition 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 210000002381 plasma Anatomy 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 230000008929 regeneration Effects 0.000 claims description 3
- 238000011069 regeneration method Methods 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000011261 inert gas Substances 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 239000008239 natural water Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000007306 turnover Effects 0.000 claims 1
- 239000006071 cream Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- -1 auxiliaries Substances 0.000 description 3
- 229910000365 copper sulfate Inorganic materials 0.000 description 3
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 229910003803 Gold(III) chloride Inorganic materials 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- RJHLTVSLYWWTEF-UHFFFAOYSA-K gold trichloride Chemical compound Cl[Au](Cl)Cl RJHLTVSLYWWTEF-UHFFFAOYSA-K 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010010957 Copper deficiency Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 102000007397 Species specific proteins Human genes 0.000 description 1
- 108020005719 Species specific proteins Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010044278 Trace element deficiency Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical compound [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/983—Blood, e.g. plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Description
Foreliggende oppfinnelse angår fremstilling av helse-konserverende og regenererende preparater, til hvilke humane blodkarakteristika for artene, typen av den givende levende organisme, f.eks. tilhørende blodtype A, B, AB, 0, Rh-positiv, Rh-negativ eller elementer derav og/eller proteiner erholdt derfra og/eller vev avledet fra animalske organismer av gitte arter eller typer og/eller elementene derav og/eller proteiner erholdt derfra påføres per se, og/eller omsettes med uorganiske substanser, f.eks. med elementer som har sporelement-funksjon i organismen, eventuelt sammen med kjente additiver, hjelpemidler, fyllstoffer, som kan anvendes ved fremstilling av helse-, kropps- og hud-konserverende preparater, og/eller i form av innvortes administrerte preparater. The present invention relates to the production of health-preserving and regenerating preparations, to which human blood characteristics for the species, the type of the donor living organism, e.g. associated blood type A, B, AB, 0, Rh-positive, Rh-negative or elements thereof and/or proteins obtained therefrom and/or tissues derived from animal organisms of given species or types and/or the elements thereof and/or proteins obtained therefrom applied per se, and/or reacted with inorganic substances, e.g. with elements that have a trace element function in the organism, possibly together with known additives, auxiliaries, fillers, which can be used in the production of health, body and skin preserving preparations, and/or in the form of internally administered preparations.
Det største særtrekk ved foreliggende oppfinnelseThe greatest distinctive feature of the present invention
ligger i anvendelse av elementene og plasmaproteiner av humant blod, ved omsetning av disse med uorganiske ioner og ved anvendelse av det erholdte produkt for kroppskonserverende bruk utvortes og/eller innvortes, f.eks. peroralt. lies in the use of the elements and plasma proteins of human blood, by reacting these with inorganic ions and by using the obtained product for body preservative use externally and/or internally, e.g. orally.
Det er kjent at mineralske substanser, sporelementene, spiller en signifikant rolle ved funksjoneringen av levende organismer også i meget små konsentrasjoner, i første rekke fordi de er komponenter av flere enzymer, enzymaktivatorer eller inhibitorer som deler av større molekyler eller ved interaksjon med disse molekyler slik at de således spiller en regulerende rolle ved organismens funksjonering. Som kjent har sporelementene en spesifikk aktivitet i den levende organisme til tross for det faktum at de er inaktive in vitro. Sporelementene utviser deres spesifikke og nødvendige effekt ved binding til de såkalte bærermolekyler og kommer derved i biologisk aktiv transport. Slike store molekyler er plasmaproteiner. Koblingen mellom sporelementene og proteinene vil etableres i organismen når betingelsene for dette sikres. It is known that mineral substances, the trace elements, play a significant role in the functioning of living organisms even in very small concentrations, primarily because they are components of several enzymes, enzyme activators or inhibitors as parts of larger molecules or by interaction with these molecules such that they thus play a regulatory role in the organism's functioning. As is known, the trace elements have a specific activity in the living organism despite the fact that they are inactive in vitro. The trace elements exhibit their specific and necessary effect by binding to the so-called carrier molecules and thereby enter into biologically active transport. Such large molecules are plasma proteins. The connection between the trace elements and the proteins will be established in the organism when the conditions for this are ensured.
Denne kobling er imidlertid ikke alltid egnet og svarer ikke til den nødvendige grad slik at effekten av sporelementene ikke fremkommer, enzymene med egnet aktivitet dannes ikke slik at hudsykdommer og mangelsykdommer vil utvikles. Ifølge litteraturdata kan mangel på sporelementer fremkalle cancerøs omdannelse i organismen, i hvilke tilfeller innføring av egnede protein/sporelementaddukter i organismen kan være for- delaktig- Således kan sporelementene ikke komme til de nød-vendige steder i organismen og vil ikke komme i en biologisk aktiv tilstand uten en transmitter og vil således ikke delta i de vitale prosesser slik at helsetilstanden vil bli ned-satt. Dette fremkommer eksempelvis når det gjelder mangel på sink, også når det gjelder den ytre forandring av huden. Sink er en komponent i minst 30 enzymer og spiller en avgjørende rolle i hudens proteinsyntese. Mangel på kobber bevirker eksempelvis at kvaliteten på ull fra sauer forringes da den fører til utilstrekkelig proteinsyntese. Sinkmetalloenzymene deltar i syntesen av DNS og RNS og mangel på disse inhiberer overføringen av genetisk informasjon som er nødvendig for dannelse av proteiner, fremkaller dvergtilbøyelighet og inhiberer regenerering av huden. Når det gjelder kobber-mangel vil hudens kollagenstruktur skades. However, this connection is not always suitable and does not respond to the necessary degree so that the effect of the trace elements does not appear, the enzymes with suitable activity are not formed so that skin diseases and deficiency diseases will develop. According to literature data, a lack of trace elements can induce cancerous transformation in the organism, in which cases the introduction of suitable protein/trace element adducts into the organism can be beneficial - Thus, the trace elements cannot get to the necessary places in the organism and will not get into a biologically active condition without a transmitter and will thus not participate in the vital processes so that the state of health will be reduced. This appears, for example, when it comes to a lack of zinc, also when it comes to the external change of the skin. Zinc is a component of at least 30 enzymes and plays a crucial role in the skin's protein synthesis. Lack of copper, for example, causes the quality of wool from sheep to deteriorate as it leads to insufficient protein synthesis. The zinc metalloenzymes participate in the synthesis of DNS and RNS and a lack of these inhibits the transfer of genetic information necessary for the formation of proteins, induces dwarfism and inhibits skin regeneration. When it comes to copper deficiency, the skin's collagen structure will be damaged.
Ifølge forsøk kan de ovenfor angitte ulemper ikke elimineres under anvendelse av mineralsubstanser per se, hvilket kan bevises ved at enkel tilsetning av jernsalter ikke vil føre til legning av sykdommer oppstått på grunn av jernmangel. Detaljene ved aktiveringsprosessene for sporelementene er ikke kjent men det er allerede bevist at de trenger et bærermolekyl slik at de kan spille deres viktige biologiske rolle. According to experiments, the above-mentioned disadvantages cannot be eliminated using mineral substances per se, which can be proven by the simple addition of iron salts will not lead to the healing of diseases caused by iron deficiency. The details of the activation processes for the trace elements are not known, but it has already been proven that they need a carrier molecule so that they can play their important biological role.
Målet ved foreliggende oppfinnelse er å eliminere de ovenfor angitte ulemper. Hovedtrekket ved foreliggende oppfinnelse består i at ved anvendelse av proteiner og sporelementer som er arts- eller type-spesifikke erholdes et addukt fra hvilket den aktive absorpsjon av sporelementer sikres, hvorved helse-konserverende og hud-regenererende preparater kan fremstilles. Anvendelse av de ovenfor angitte komponenter eliminerer den uønskede antigeneffekt, fremkaller ikke aller-giske reaksjoner og sikrer en hurtig regenerering av de skadede celler i huden og den tilstrekkelige funksjon av metallo-enzymene. Det er funnet at den hud-regenererende krem fremstilt ifølge oppfinnelsen har leget eksempelvis et sår på nesen av plommestenstørrelse som hadde væsket i 15 år og som ble betraktet som uhelbredelig, ved påføring av denne to ganger pr. dag i 8 dager slik at huden på nesen var blitt fullstendig regenerert og såret ikke etterlot noe spor. I andre tilfeller har kremen fremstilt ifølge oppfinnelsen regenerert avskallet hud på en rotte i løpet av 6 dager i en slik grad at selv hår er vokst ut på den avskallede hudoverflate mens huden på kontrolldyret var fullstendig skadet. Kremen ifølge oppfinnelsen kan påføres med fordel eksempelvis på hud med psoriasis. The aim of the present invention is to eliminate the above-mentioned disadvantages. The main feature of the present invention is that by using proteins and trace elements that are species- or type-specific, an adduct is obtained from which the active absorption of trace elements is ensured, whereby health-preserving and skin-regenerating preparations can be prepared. Use of the above-mentioned components eliminates the unwanted antigenic effect, does not cause allergic reactions and ensures a rapid regeneration of the damaged cells in the skin and the adequate functioning of the metallo-enzymes. It has been found that the skin-regenerating cream produced according to the invention has healed, for example, a pumice-sized wound on the nose which had been oozing for 15 years and which was considered incurable, by applying it twice a week. day for 8 days so that the skin on the nose was completely regenerated and the wound left no trace. In other cases, the cream produced according to the invention has regenerated peeled skin on a rat within 6 days to such an extent that even hair has grown on the peeled skin surface, while the skin of the control animal was completely damaged. The cream according to the invention can be applied with advantage, for example, to skin with psoriasis.
Det helse-konserverende og regenererende preparatThe health-preserving and regenerating preparation
ifølge oppfinnelsen kan også påføres innvortes. Adduktet av sporelementene og de arts, typespesifikke proteiner sikrer de absorberbare sporelementer også for enzymsystemet som er nød-vendig for funksjonering av hele organismen. Dette muliggjør en optimal funksjonering av organismen idet man tar i betraktning en spesfikk status av organismen. according to the invention can also be applied internally. The adduct of the trace elements and the species-specific proteins ensures the absorbable trace elements also for the enzyme system which is necessary for the functioning of the entire organism. This enables optimal functioning of the organism, taking into account a specific status of the organism.
Følgelig angår oppfinnelsen et artsspesifikt, type-spesifikt helse-konserverende preparat som kan påføres både innvortes og utvortes, og som erkarakterisert vedat det fremstilles fra sporelementer og proteiner, proteinholdige substanser som er karakteristiske for de gitte arter og typer hvorpå det erholdte preparat anvendes for helse-konservering av en levende organisme av samme art og type. Accordingly, the invention relates to a species-specific, type-specific health-preserving preparation which can be applied both internally and externally, and which is characterized by the fact that it is produced from trace elements and proteins, proteinaceous substances which are characteristic of the given species and types on which the obtained preparation is used for health - conservation of a living organism of the same species and type.
Fremstilling av de helse-konserverende og regenererende preparater ifølge oppfinnelsen illustreres i de etterfølgende Production of the health-preserving and regenerating preparations according to the invention is illustrated in the following
- ikke eksempler.- not examples.
Eksempel 1Example 1
100 ml humant blod tilhørende gruppe A ble separert100 ml of human blood belonging to group A was separated
for plasma og blodelementer. Til den erholdte plasmavæske ble tilsatt 1 g natriumbicarbonat og reaksjonsblandingen ble oppvarmet til 80°C. Proteinpresipitatet ble fraskilt, og etter tørking eller til det fremdeles våte plasmaprotein med et tørrstoffinnhold på 3,5 g ble 70 ml av en vandig løsning inneholdende 35 ug jern(II), 35 ug sink(II), 10 ug kobber(II), for plasma and blood elements. 1 g of sodium bicarbonate was added to the plasma fluid obtained and the reaction mixture was heated to 80°C. The protein precipitate was separated, and after drying or to the still wet plasma protein with a dry matter content of 3.5 g, 70 ml of an aqueous solution containing 35 µg iron(II), 35 µg zinc(II), 10 µg copper(II),
10 ug sølv(I), 1 ug krom(III), 2 ug mangan(XI), 1 ug gull(III) ioner såvel som 1 ug bor og 1 ug molybdenioner tilsatt. Reaksjonsblandingen ble behandlet i et bad på 100°C i 60 minutter, og etter avkjøling ble 100 g krem fremstilt fra den er- 10 ug silver(I), 1 ug chromium(III), 2 ug manganese(XI), 1 ug gold(III) ions as well as 1 ug boron and 1 ug molybdenum ions added. The reaction mixture was treated in a bath at 100°C for 60 minutes, and after cooling, 100 g of cream was prepared from the
holdte substans på kjent måte innen kosmetikkfaget. Det således erholdte produkt er et glimrende hudmiddel som er egnet for behandling av skadede hudoverflater. held substance in a manner known in the field of cosmetics. The product thus obtained is an excellent skin agent which is suitable for the treatment of damaged skin surfaces.
Eksempel 2Example 2
Fremgangsmåten ifølge eksempel 1 ble fulgt men plasma-proteinene og de uorganiske substanser ble behandlet ved 121°C i 35 minutter. The procedure of Example 1 was followed but the plasma proteins and inorganic substances were treated at 121°C for 35 minutes.
Eksempel 3Example 3
Fremgangsmåten ifølge eksempel 1 eller 2 ble fulgt men griseblod ble anvendt, og produktet erholdt etter varme-behandling ble anvendt for tilførsel av mangel på sporelementer til griser per se ved påføring som salve på huden eller ved peroral administrering. The procedure according to example 1 or 2 was followed, but pig blood was used, and the product obtained after heat treatment was used for supplying trace element deficiencies to pigs per se by application as an ointment to the skin or by oral administration.
Eksempel 4Example 4
Fremgangsmåten ifølge eksempel 1 ble fulgt men humant blod tilhørende gruppe B ble anvendt. The procedure according to example 1 was followed but human blood belonging to group B was used.
Eksempel 5Example 5
Fremgangsmåten ifølge eksempel 1 ble fulgt men 70 ml Héviz medisinsk vann ble anvendt i stedet for den vandige løsning inneholdende uorganiske substanser. The procedure according to Example 1 was followed but 70 ml of Héviz medicinal water was used instead of the aqueous solution containing inorganic substances.
Eksempel 6Example 6
Fremgangsmåten ifølge eksempel 1 til 4 ble fulgt men proteinet ble omsatt med medisinsk vann fra Csåszårbath, Budapest. The procedure according to examples 1 to 4 was followed but the protein was reacted with medicinal water from Csåszårbath, Budapest.
Eksempel 7Example 7
Fremgangsmåten ifølge eksempel 1 til 4 ble fulgt men et mineralsk vann, f.eks. Parådivann ble anvendt i stedet for den vandige løsning fremstilt i eksempel 1. The procedure according to examples 1 to 4 was followed but a mineral water, e.g. Purified water was used instead of the aqueous solution prepared in example 1.
Eksempel 8Example 8
Til 10 liter blodplasma fra okse ble tilsatt 25 ml vann, 100 mg kobbersulfat og 100 mg sinksulfat, og reaksjonsblandingen ble holdt ved 121°C i 60 minutter. Det erholdte produkt ble påført ved sprøyting på huden eller håret på dyr eller ved vanning for behandling av sykdommer på grunn av mangel av sporelementer. To 10 liters of blood plasma from an ox, 25 ml of water, 100 mg of copper sulfate and 100 mg of zinc sulfate were added, and the reaction mixture was kept at 121°C for 60 minutes. The product obtained was applied by spraying to the skin or hair of animals or by irrigation for the treatment of diseases due to a lack of trace elements.
EksempelExample
Til det tørre plasmapulver erholdt fra humant blod fra gruppe 0 ifølge eksempel 1 ble tilsatt 400 ml vann og 0,5 ml kommersielt "Béres-csepp" inneholdende sporelementer. Reaksjonsblandingen ble behandlet ved 121°C i 35 minutter og ble deretter bearbeidet til en krem på kjent måte. Kremen er egnet for regenerering av hud med varmeskader. To the dry plasma powder obtained from human blood from group 0 according to example 1, 400 ml of water and 0.5 ml of commercial "Béres-csepp" containing trace elements were added. The reaction mixture was treated at 121°C for 35 minutes and was then processed to a cream in a known manner. The cream is suitable for the regeneration of skin with heat damage.
Eksempel 10Example 10
Fremgangsmåten ifølge eksempel 1 til 9 ble fulgt men proteinet inneholdende substanser ble varmebehandlet i et medium fritt for oxygen eller nærvær av en inert gass. The procedure according to examples 1 to 9 was followed but the protein containing substances was heat treated in a medium free of oxygen or the presence of an inert gas.
Eksempel 11Example 11
Fremgangsmåten ifølge eksempel 1 eller 9 ble fulgt, men preparatet ble fremstilt fra vevet fra organismen av den angjeldende person. The procedure according to example 1 or 9 was followed, but the preparation was prepared from the tissue of the organism of the person concerned.
Eksempel 12Example 12
100 ml humant blod ble separert for plasmavæske og blodelementer. Til plasmaet ble tilsatt 80 ug jern(III)sulfat, 8 ug mangan(II)klorid, 40 ug sinkklorid, 40 ug kobbersulfat, 80 jag kaliumklorid, 4 ug hver av borsyre, sølvnitrat og gull (III)klorid, og reaksjonsblandingen ble omrørt ved 36°C i 30 minutter. Den erholdte løsning ble påført parenteralt. 100 ml of human blood was separated for plasma fluid and blood elements. To the plasma was added 80 µg iron (III) sulfate, 8 µg manganese (II) chloride, 40 µg zinc chloride, 40 µg copper sulfate, 80 µg potassium chloride, 4 µg each of boric acid, silver nitrate and gold (III) chloride, and the reaction mixture was stirred at 36°C for 30 minutes. The obtained solution was applied parenterally.
Eksempel 13Example 13
Til 8 g tørt, hydrofilt humant blodplasma ble tilsatt 400 ml fysiologisk natriumklorid hvori 160 ug jern.(II)sulfat, 16 ug mangan(II)klorid, 80 ug sinkklorid, 80 pg kobbersulfat, To 8 g of dry, hydrophilic human blood plasma was added 400 ml of physiological sodium chloride in which 160 ug of iron (II) sulfate, 16 ug of manganese (II) chloride, 80 ug of zinc chloride, 80 pg of copper sulfate,
60 ug kaliumklorid og 8 |ug hver av sølvnitrat, borsyre og gull(III)klorid på forhånd var blitt oppløst. Reaksjonsblandingen ble sterilisert i. en forseglet beholder ved 121°C 60 µg of potassium chloride and 8 µg each of silver nitrate, boric acid and gold(III) chloride had previously been dissolved. The reaction mixture was sterilized in a sealed container at 121°C
i 30 minutter. Den erholdte løsning ble påført parenteralt. for 30 minutes. The obtained solution was applied parenterally.
Claims (7)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU833582A HUT37342A (en) | 1983-10-17 | 1983-10-17 | Process for production of preparatives for medical cosmetics |
Publications (1)
Publication Number | Publication Date |
---|---|
NO852427L true NO852427L (en) | 1985-06-14 |
Family
ID=10964641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO852427A NO852427L (en) | 1983-10-17 | 1985-06-14 | PROCEDURE FOR THE MANUFACTURE OF MEDICAL, COSMETIC PREPARATIONS |
Country Status (12)
Country | Link |
---|---|
JP (1) | JPS61500358A (en) |
KR (1) | KR850700008A (en) |
AU (1) | AU3551084A (en) |
DE (1) | DE3490488T1 (en) |
DK (1) | DK273585A (en) |
FI (1) | FI852341A0 (en) |
GB (1) | GB2164848A (en) |
HU (1) | HUT37342A (en) |
NL (1) | NL8420264A (en) |
NO (1) | NO852427L (en) |
SE (1) | SE8502997D0 (en) |
WO (1) | WO1985001653A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1243957A (en) * | 1983-06-03 | 1988-11-01 | Laszlo Bogdany | Compositions for cosmetic, health- and body- preserving use |
FR2572287A1 (en) * | 1984-10-26 | 1986-05-02 | Caola Kozmetikai | Process for preparing medicinal cosmetic compositions |
AU617661B2 (en) * | 1987-02-24 | 1991-12-05 | Thermalife International Pharmaceuticals Limited | A method for manufacturing cosmetical, health and body care products |
US5527779A (en) * | 1988-03-23 | 1996-06-18 | Top Gold Pty Limited | Topically applied gold organic complex |
NZ228367A (en) * | 1988-03-23 | 1992-02-25 | Smithkline Beecham Corp | Topical composition containing a gold compound for treating inflammatory conditions |
US5013726A (en) * | 1989-09-12 | 1991-05-07 | Ivy Jeffery W | External analgesic lotion containing active ingredients of methyl salicylate and camphor and menthol and method of making such lotion |
US5124320A (en) * | 1989-09-12 | 1992-06-23 | Ivy Jeffery W | An external analgesic lotion containing active ingredients of camphor and menthol and method of making such lotion |
US20070048387A1 (en) * | 2005-09-01 | 2007-03-01 | Edwards Jeffrey D | Tissue disruption treatment and composition for use thereof |
CN103033632B (en) * | 2012-12-12 | 2014-10-22 | 英科新创(厦门)科技有限公司 | Reverse typing colloidal gold kit for ABO blood groups and preparation method thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU101771A1 (en) * | 1954-05-04 | 1900-01-01 | А.А. Дыскин | The carbonation method of citrate donated blood and a device for implementing the method |
SU523695A1 (en) * | 1973-12-14 | 1976-08-05 | Курганский Научно-Исследовательский Институт Экспериментальной И Клинической Ортопедии И Травматологии | Method to stop bleeding |
SU777903A1 (en) * | 1978-12-26 | 1981-12-15 | Ленинградский Ордена Трудового Красного Знамени Научно-Исследовательский Институт Гематологии И Переливания Крови | Method of producing aminoacid compound for parenteral nutrition |
SU741877A1 (en) * | 1979-06-06 | 1980-06-25 | За витель Р. Н. Ходанова | Allergic desease treating method |
-
1983
- 1983-10-17 HU HU833582A patent/HUT37342A/en unknown
-
1984
- 1984-10-17 AU AU35510/84A patent/AU3551084A/en not_active Abandoned
- 1984-10-17 DE DE19843490488 patent/DE3490488T1/en not_active Withdrawn
- 1984-10-17 WO PCT/HU1984/000050 patent/WO1985001653A1/en active Application Filing
- 1984-10-17 JP JP59504031A patent/JPS61500358A/en active Pending
- 1984-10-17 GB GB08514467A patent/GB2164848A/en not_active Withdrawn
- 1984-10-17 KR KR1019850700088A patent/KR850700008A/en not_active Application Discontinuation
- 1984-10-17 NL NL8420264A patent/NL8420264A/en unknown
-
1985
- 1985-06-12 FI FI852341A patent/FI852341A0/en not_active Application Discontinuation
- 1985-06-14 NO NO852427A patent/NO852427L/en unknown
- 1985-06-17 SE SE8502997A patent/SE8502997D0/en not_active Application Discontinuation
- 1985-06-17 DK DK273585A patent/DK273585A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DK273585D0 (en) | 1985-06-17 |
SE8502997L (en) | 1985-06-17 |
GB8514467D0 (en) | 1985-07-10 |
DE3490488T1 (en) | 1985-10-17 |
WO1985001653A1 (en) | 1985-04-25 |
JPS61500358A (en) | 1986-03-06 |
FI852341L (en) | 1985-06-12 |
GB2164848A (en) | 1986-04-03 |
KR850700008A (en) | 1985-10-21 |
FI852341A0 (en) | 1985-06-12 |
DK273585A (en) | 1985-06-17 |
NL8420264A (en) | 1985-09-02 |
AU3551084A (en) | 1985-05-07 |
HUT37342A (en) | 1985-12-28 |
SE8502997D0 (en) | 1985-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1277599C (en) | Vanadium - peroxide compositions as insulin mimickers | |
CA2298645C (en) | Use of physiologically acceptable vanadium compounds, salts and complexes | |
NO852427L (en) | PROCEDURE FOR THE MANUFACTURE OF MEDICAL, COSMETIC PREPARATIONS | |
Sander et al. | Evidence for function of a metal ion in the activity of dihydroorotase from Zymobacterium oroticum | |
KR100828494B1 (en) | A composition of a cosmetic essense and the method of prepating it for improvenent of wrinkle | |
US4863897A (en) | Protein and mineral water-containing cosmetic compositions | |
US4839347A (en) | Composition for treating dehydration | |
JP2004510402A (en) | Acidic solution of poorly soluble group IIA complex | |
FR2546754A1 (en) | COSMETIC AGENTS FOR THE CARE OF HEALTH AND BODY | |
Carruthers et al. | Biochemistry and physiology of epidermis | |
RU2399367C1 (en) | Method of thrombin clotting time optimisation for newborn piglets with anaemia | |
Hirsch | Tissue Autoxidation Inhibitors: I. The Inhibition of DOPA Autoxidation by Extracts from Normal and Neoplastic Tissues | |
FR2572287A1 (en) | Process for preparing medicinal cosmetic compositions | |
Nomura et al. | CIII The Capillary in the Human Vestibular Labyrinth: A Histochemical Staining Technique | |
US3017325A (en) | Therapeutic composition for topical application and method of applying the same | |
Sheker et al. | Silver allantoinate for the topical treatment of burns | |
BE900935A (en) | Prodn. of medicinal cosmetic compsns. - from human blood | |
Carroll | Phenolsulfotransferase in the developing rat | |
RU2392927C1 (en) | Method of normalising antiplasmin level in anemia of newborn calves and pigs | |
RU2406483C2 (en) | METHOD OF α2 ANTIPLASMIN LEVEL REDUCTION IN NEWBORN PIGLETS WITH ANAEMIA | |
RU2818836C1 (en) | Method for iron deficiency anemia correction in sucking calves | |
RU2383334C1 (en) | Method for normalisation of fibrin content in blood in neonatal piglets with anaemia | |
CN103232538B (en) | Sulfhydrylation modified collagen calcium compound | |
SU829115A1 (en) | Method of treating and prophylaxis of gastro-intestinal disturbances of agricultural animals | |
RU2349308C1 (en) | METHOD OF α2 ANTIPLASMIN LEVEL STABILISATION FOR NEWBORN PIGLETS WITH ANAEMIA |